Lignaron

Lenalidomide, the active ingredient in Lignaron, is an immunomodulatory drug (IMiD) presented as an oral formulation for systemic use. It is employed in the treatment of certain hematologic malignancies, including multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma, and is prescribed for adult patients under specialist supervision in clinical practice and may be part of combination regimens. The drug exerts anti‑proliferative and immunomodulatory actions that contribute to disease control.

GNH USA supplies Lignaron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is used in hematologic oncology to target malignant plasma cells and related disorders. - Multiple myeloma: improves progression‑free survival and overall response rates, often in combination with dexamethasone, for adult patients. - Myelodysplastic syndromes with del(5q): reduces red‑cell transfusion dependence and can achieve cytogenetic remission, administered to adults with this chromosomal abnormality. - Mantle cell lymphoma: provides therapeutic benefit in relapsed or refractory disease, frequently used within multi‑agent protocols for adult patients.

Lenalidomide is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness that may limit physical activity. - Diarrhea: frequent loose stools that can lead to dehydration if untreated. - Nausea: mild to moderate stomach upset, sometimes accompanied by vomiting. - Rash: skin redness or itching that may appear on trunk or limbs. - Constipation: difficulty passing stool, occasionally causing abdominal discomfort. - Peripheral neuropathy: tingling, numbness, or burning sensations in hands or feet.

Serious or Rare Side Effects: - Thromboembolic events: formation of blood clots such as deep‑vein thrombosis or pulmonary embolism, requiring immediate medical attention. - Severe neutropenia: marked reduction in neutrophil count, increasing susceptibility to serious infections. - Hepatotoxicity: significant elevation of liver enzymes or liver injury, monitored through laboratory tests. - Secondary primary malignancies: development of new, unrelated cancers during or after therapy. - Severe skin reactions: life‑threatening conditions like Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing lenalidomide, clinicians should observe several safety precautions to minimize risks. - Pregnancy risk: contraindicated in pregnancy (Category X); effective contraception required for both patient and male partners. - Thromboembolism prophylaxis: assess need for anticoagulation, especially when combined with corticosteroids or immunomodulators. - Hematologic monitoring: perform regular complete blood counts to detect neutropenia or anemia. - Renal function: adjust use in patients with impaired kidney function and monitor creatinine levels. - Infection vigilance: watch for signs of infection due to immunosuppression. - Store at ambient temperature: keep tablets in original container, protect from moisture and light, and store below 25 °C.

Lenalidomide may interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers: agents such as rifampin can lower lenalidomide exposure. - Anticoagulants: concurrent use may increase bleeding risk; careful monitoring required. - Immunosuppressants: combined use may heighten infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates: drugs like midazolam may have altered levels. - P-glycoprotein inhibitors: agents such as verapamil can increase lenalidomide concentrations. - Hormonal contraceptives: efficacy may be reduced; alternative contraception advised.